National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Last Modified: 10/20/2008     First Published: 6/25/2005  

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Basic Trial Information

Phase
 Type
 Status
 Age
 Sponsor
 Protocol IDs

Phase III
Treatment
Active
18 and over
NCI
CALGB-50303
CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209

Special Category: NIH Clinical Center trial

Objectives

Primary

  1. Compare the event-free survival of patients with previously untreated de novo diffuse large B-cell non-Hodgkin's lymphoma treated with R-CHOP comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone vs EPOCH-R comprising etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab.
  2. Determine molecular predictors of outcome (using molecular profiling) in patients treated with these regimens.

Secondary

  1. Compare the response rate and overall survival of patients treated with these regimens.
  2. Compare the toxicity of these regimens in these patients.
  3. Correlate the clinical parameters (i.e., toxicity, response, survival outcomes, and laboratory results) with molecular profiling in patients treated with these regimens.
  4. Determine the use of molecular profiling for pathological diagnosis in patients treated with these regimens.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed* de novo B-cell non-Hodgkin's lymphoma (NHL) of 1 of the following WHO histologic subtypes:
    • Diffuse large cell lymphoma, including any of the following morphologic variants:
      • Centroblastic
      • Immunoblastic
      • T-cell/histiocyte rich
      • Anaplastic
    • Mediastinal (thymic) large cell lymphoma
    • Intravascular large cell lymphoma

     [Note: *Fine needle aspirates or core biopsies must not be the only diagnostic material]



  • Stage I primary mediastinal (thymic) OR stage II-IV disease


  • CD20-positive disease


  • No underlying low-grade lymphoma (e.g., transformed lymphoma or low-grade lymphoma in the bone marrow)


  • No known lymphomatous CNS involvement
    • Lumbar puncture required unless there are no neurological symptoms


 [Note: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.]

Prior/Concurrent Therapy:

Biologic therapy

  • No prior rituximab

Chemotherapy

  • No prior chemotherapy for other malignancies
  • No prior cytotoxic chemotherapy
  • No other concurrent chemotherapy

Endocrine therapy

  • Prior short course (< 10 days) glucocorticoids allowed for an urgent local disease complication (e.g., cord compression or superior vena cava syndrome) at diagnosis
  • No concurrent hormonal therapy except steroids for adrenal failure or hormones for non-disease related conditions (e.g., insulin for diabetes)
  • No concurrent dexamethasone or other steroidal antiemetics

Radiotherapy

  • Prior limited field radiotherapy allowed for an urgent local disease complication (e.g., cord compression or superior vena cava syndrome) at diagnosis
  • No concurrent radiotherapy except for isolated CNS lesions

Surgery

  • Not specified

Other

  • No other concurrent investigational or commercial agents or therapies for NHL

Patient Characteristics:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • Absolute neutrophil count ≥ 1,000/mm3*
  • Platelet count ≥ 100,000/mm3*
  • No active bleeding unrelated to NHL

 [Note: *Unless due to NHL]

Hepatic

  • Bilirubin ≤ 2 mg/dL*

 [Note: *Unless due to NHL or Gilbert's disease]

Renal

  • Creatinine ≤ 1.5 mg/dL*

    OR

  • Creatinine clearance ≥ 50 mL/min*

 [Note: *Unless due to NHL]

Cardiovascular

  • No active ischemic heart disease
  • No congestive heart failure

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No active uncontrolled bacterial or viral infection unrelated to NHL
  • No other active medical process unrelated to NHL

Expected Enrollment

478

A total of 478 patients (239 per treatment arm) will be accrued for this study within 4.5 years.

Outcomes

Primary Outcome(s)

Event-free survival 5 years after completion of study treatment

Secondary Outcome(s)

R-CHOP and DA-EPOCH-R molecular predictors of outcome as measured by cDNA microarray 5 years after completion of study treatment

Outline

This is a randomized, multicenter study. Patients are stratified according to International Prognostic Index score. Patients are randomized to 1 of 2 treatment arms.

  • Arm I (R-CHOP): Patients receive rituximab IV, cyclophosphamide IV, doxorubicin IV over 3-5 minutes, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.


  • Arm II (EPOCH-R): Patients receive rituximab IV on day 1, doxorubicin IV, etoposide IV, and vincristine IV continuously over 96 hours on days 1-4, cyclophosphamide IV on day 5, and oral prednisone twice daily on days 1-5. Patients also receive filgrastim (G-CSF) once daily on days 2-11 or until blood counts recover. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.


After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for up to 3 years.

Trial Contact Information

Trial Lead Organizations

Cancer and Leukemia Group B

Wyndham Wilson, MD, PhD, Protocol chair
Ph: 301-435-2415
Email: wilsonw@mail.nih.gov
Andrew D. Zelenetz, MD, PhD, Protocol co-chair
Ph: 212-639-2656; 800-525-2225

Trial Sites

U.S.A.
Alabama
  Anniston
 Regional Medical Center
 Ellen Spremulli
Ph: 256-235-5877
Alaska
  Anchorage
 Providence Cancer Center
 Clinical Trials Office - Providence Cancer Center
Ph: 907-261-3109
California
  Burbank
 Providence Saint Joseph Medical Center - Burbank
 Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank
Ph: 818-847-3220
  Mountain View
 Camino Medical Group - Treatment Center
 Peter Yu, MD
Ph: 408-524-5085
  Orange
 St. Joseph Hospital Regional Cancer Center - Orange
 Tiberio Lindgren
Ph: 714-771-8999
  Palm Springs
 Desert Regional Medical Center Comprehensive Cancer Center
 Clinical Trials Office - Desert Regional Medical Center Comprehensive Cancer Center
Ph: 760-416-4730
  Palo Alto
 Palo Alto Medical Foundation
 Peter Yu, MD
Ph: 408-524-5085
  Sacramento
 University of California Davis Cancer Center
 Clinical Trials Office - University of California Davis Cancer Center
Ph: 916-734-3089
  San Diego
 Naval Medical Center - San Diego
 Preston Gable, MD, FACP
Ph: 619-532-7303
  San Francisco
 UCSF Helen Diller Family Comprehensive Cancer Center
 Clinical Trials Office - UCSF Helen Diller Family Comprehensive Cancer Center
Ph: 877-827-3222
Colorado
  Colorado Springs
 Memorial Hospital Cancer Center - Colorado Springs
 Clinical Trials Office - Memorial Hospital
Ph: 719-365-2406
  Fort Collins
 Front Range Cancer Specialists
 Diana Medgyesy, MD
Ph: 970-212-7600
 Poudre Valley Hospital
 Clinical Trials Office - Poudre Valley Hospital
Ph: 970-495-8226
Connecticut
  Farmington
 Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
 Clinical Trials Office - Carole and Ray Neag Comprehensive Cancer Center
Ph: 800-579-7822
  Hartford
 Helen and Harry Gray Cancer Center at Hartford Hospital
 Clinical Trials Office - Helen and Harry Gray Cancer Center
Ph: 860-545-5363
  Norwich
 Eastern Connecticut Hematology and Oncology Associates
 Dennis Slater, MD
Ph: 860-886-8362
Delaware
  Lewes
 Tunnell Cancer Center at Beebe Medical Center
 Clinical Trials Office - Tunnell Cancer Center
Ph: 302-645-3171
  Newark
 CCOP - Christiana Care Health Services
 Clinical Trial Office - CCOP - Christiana Care Health Services
Ph: 302-733-6227
District of Columbia
  Washington
 Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
 Clinical Trials Office - Lombardi Comprehensive Cancer Center
Ph: 202-444-0381
 Sibley Memorial Hospital
 Bruce Kressel, MD, FACP
Ph: 202-537-4000
 Walter Reed Army Medical Center
 Clinical Trials Office - Walter Reed Army Medical Center
Ph: 202-782-7840
Florida
  Fort Lauderdale
 Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
 Clinical Trials Office - Michael and Dianne Bienes Comprehensive Cancer Center
Ph: 954-776-3239
  Jupiter
 Ella Milbank Foshay Cancer Center at Jupiter Medical Center
 Clinical Trials Office - Ella Milbank Foshay Cancer Center
Ph: 561-745-5768
  Weston
 Cleveland Clinic Florida - Weston
 Clinical Trials Office - Cleveland Clinic Florida - Weston
Ph: 954-659-5705
Georgia
  Augusta
 Augusta Oncology Associates - Walton Way
 Mark Keaton, MD
Ph: 706-821-2944
  Columbus
 John B. Amos Cancer Center
 Clinical Trials Office - John B. Amos Cancer Center
Ph: 706-660-6404
  Macon
 Medical Center of Central Georgia
 Frederick Schnell, MD, FACP
Ph: 478-743-7068
Illinois
  Aurora
 Rush-Copley Cancer Care Center
 Kendrith Rowland, MD
Ph: 217-383-3010
  Chicago
 Hematology and Oncology Associates
 Clinical Trails Office - Hematology and Oncology Associates
Ph: 312-695-1301
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Ph: 312-695-1301
 Email: cancer@northwestern.edu
 University of Chicago Cancer Research Center
 Clinical Trials Office - University of Chicago Cancer Research Center
Ph: 773-834-7424
  Joliet
 Joliet Oncology-Hematology Associates, Limited - West
 Sanjiv Modi
Ph: 815-730-3098
 Midwest Center for Hematology/Oncology
 Jane Winter, MD
Ph: 312-695-6180
  Libertyville
 North Shore Oncology and Hematology Associates, Limited - Libertyville
 Jane Winter, MD
Ph: 312-695-6180
  Maywood
 Cardinal Bernardin Cancer Center at Loyola University Medical Center
 Clinical Trials Office - Cardinal Bernardin Cancer Center
Ph: 708-226-4357
  Olympia Fields
 Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
 Clinical Trials Office - Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
Ph: 708-679-2217
  Skokie
 Hematology Oncology Associates - Skokie
 Jane Winter, MD
Ph: 312-695-6180
  Urbana
 Carle Cancer Center at Carle Foundation Hospital
 Clinical Trials Office - Carle Cancer Center
Ph: 800-446-5532
 CCOP - Carle Cancer Center
 Clinical Trials Office - CCOP - Carle Cancer Center
Ph: 800-446-5532
Indiana
  Fort Wayne
 Fort Wayne Medical Oncology and Hematology
 Sreenivasa Nattam, MD
Ph: 260-484-8830
800-852-2333
  Michigan City
 Saint Anthony Memorial Health Centers
 Kendrith Rowland, MD
Ph: 217-383-3010
  Munster
 Community Hospital
 Erwin Robin, MD
Ph: 219-836-4503
Iowa
  Ames
 McFarland Clinic, PC
 Clinical Trials Office - McFarland Clinic, PC
Ph: 515-239-2621
  Cedar Rapids
 Cedar Rapids Oncology Associates
 Clinical Trials Office - Cedar Rapids Oncology Associates
Ph: 319-363-2690
  Sioux City
 Mercy Medical Center - Sioux City
 Donald Wender, MD, PhD
Ph: 712-252-9326
 Siouxland Hematology-Oncology Associates, LLP
 Donald Wender, MD, PhD
Ph: 712-252-9326
 St. Luke's Regional Medical Center
 Donald Wender, MD, PhD
Ph: 712-252-9326
Kansas
  Topeka
 Cotton-O'Neil Cancer Center
 Clinical Trials Office - Cotton-O'Neil Cancer Center
Ph: 785-270-4963
Kentucky
  Louisville
 James Graham Brown Cancer Center at University of Louisville
 Roger Herzig
Ph: 502-562-4158
866-530-5516
Maine
  Waterville
 MaineGeneral Medical Center - Waterville
 Clinical Trials Office - MaineGeneral Medical Center - Waterville
Ph: 207-872-1792
Maryland
  Baltimore
 Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
 Stephen J. Noga, MD, PhD
Ph: 410-601-4734
 Greenebaum Cancer Center at University of Maryland Medical Center
 Clinical Trials Office - Greenebaum Cancer Center at University of Maryladn Medical Center
Ph: 800-888-8823
  Bethesda
 NIH - Warren Grant Magnuson Clinical Center
 Clinical Trials Office - NIH - Warren Grant Magnuson Clinical Center
Ph: 800-411-1222
  Elkton MD
 Union Hospital Cancer Program at Union Hospital
 Stephen Grubbs, MD
Ph: 410-398-4000
  Kensington
 Associates in Oncology and Hematology
 Paul Thambi
Ph: 301-929-0765
  Rockville
 Associates in Oncology and Hematology - Medical Center Drive
 Paul Thambi
Ph: 301-424-6231
Massachusetts
  Boston
 Massachusetts General Hospital
 Clinical Trials Office - Massachusetts General Hospital
Ph: 877-726-5130
Michigan
  Battle Creek
 Battle Creek Health System Cancer Care Center
 Marianne Lange, MD
Ph: 616-966-8000
  Big Rapids
 Mecosta County Medical Center
 Marianne Lange, MD
Ph: 231-796-8691
  Escanaba
 Green Bay Oncology, Limited - Escanaba
 Thomas Saphner, MD, FACP
Ph: 800-432-6049
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Marianne Lange, MD
Ph: 616-391-2799
 CCOP - Grand Rapids
 Marianne Lange, MD
Ph: 616-391-1230
 Lacks Cancer Center at Saint Mary's Health Care
 Marianne Lange, MD
Ph: 616-752-5222
  Holland
 Holland Community Hospital
 Marianne Lange, MD
Ph: 616-392-5141
  Iron Mountain
 Dickinson County Healthcare System
 Thomas Saphner, MD, FACP
Ph: 906-774-1313
  Kalamazoo
 Borgess Medical Center
 Raymond Lord, MD
Ph: 269-373-7488
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7488
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Muskegon
 Hackley Hospital
 Marianne Lange, MD
Ph: 231-726-3511
  Southfield
 Providence Cancer Institute at Providence Hospital - Southfield Campus
 Howard Terebelo, DO
Ph: 248-552-0620
  Traverse City
 Munson Medical Center
 Marianne Lange, MD
Ph: 231-935-6202
  Wyoming
 Metro Health Hospital
 Marianne Lange, MD
Ph: 616-252-7200
Minnesota
  Minneapolis
 Veterans Affairs Medical Center - Minneapolis
 Clinical Trials Office - Veterans Affairs Medical Center - Minneapolis
Ph: 612-467-2800
Missouri
  Columbia
 Ellis Fischel Cancer Center at University of Missouri - Columbia
 Clinical Trial Office - Ellis Fischel Cancer Center
Ph: 573-882-4894
  Saint Louis
 Christian Hospital Northeast Cancer Care Center
 Timothy Rearden, MD
Ph: 314-653-5733
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Nancy Bartlett, MD
Ph: 314-362-4843
Montana
  Billings
 Billings Clinic - Downtown
 Clinical Trials Office - Billings Clinic - Downtown
Ph: 800-996-2663
 Email: research@billingsclinic.org
 CCOP - Montana Cancer Consortium
 Benjamin Marchello, MD
Ph: 406-259-2245
800-361-3239
 Hematology-Oncology Centers of the Northern Rockies - Billings
 Benjamin Marchello, MD
Ph: 406-238-6290
800-648-6274
 Northern Rockies Radiation Oncology Center
 Benjamin Marchello, MD
Ph: 406-248-2212
800-358-8818
 St. Vincent Healthcare Cancer Care Services
 Benjamin Marchello, MD
Ph: 406-657-7000
  Bozeman
 Bozeman Deaconess Cancer Center
 Benjamin Marchello, MD
Ph: 406-585-5070
  Butte
 St. James Healthcare Cancer Care
 Benjamin Marchello, MD
Ph: 406-723-2500
  Great Falls
 Benjamin Marchello, MD
 Big Sky Oncology
 Clinical Trail Office - Big Sky Oncology
Ph: 406-731-8217
 Great Falls Clinic - Main Facility
 Benjamin Marchello, MD
Ph: 406-454-2171
800-421-1649
 Sletten Cancer Institute at Benefis Healthcare
 Grant Harrer, MD, FACP, CCTI
Ph: 406-455-2820
  Helena
 St. Peter's Hospital
 Benjamin Marchello, MD
Ph: 406-442-2480
  Kalispell
 Glacier Oncology, PLLC
 Benjamin Marchello, MD
Ph: 406-752-7600
 Kalispell Medical Oncology at KRMC
 Benjamin Marchello, MD
Ph: 406-752-8900
 Kalispell Regional Medical Center
 Benjamin Marchello, MD
Ph: 406-752-5111
  Missoula
 Community Medical Center
 Benjamin Marchello, MD
Ph: 406-728-4100
 Guardian Oncology and Center for Wellness
 Benjamin Marchello, MD
Ph: 406-721-1118
 Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
 Clinical Trials Office - Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Ph: 406-329-7029
 Montana Cancer Specialists at Montana Cancer Center
 Clinical Trials Office - Montana Cancer Specialists at Montana Cancer Center
Ph: 406-238-6962
Nebraska
  Omaha
 Methodist Estabrook Cancer Center
 Robert Langdon, MD
Ph: 402-354-5890
877-850-3212
Nevada
  Las Vegas
 CCOP - Nevada Cancer Research Foundation
 John Ellerton, MD, CM
Ph: 702-384-0013
 University Medical Center of Southern Nevada
 John Ellerton, MD, CM
Ph: 702-383-2000
New Hampshire
  Manchester
 Elliot Regional Cancer Center at Elliot Hospital
 Douglas Weckstein, MD
Ph: 603-663-4201
New Jersey
  Voorhees
 Cancer Institute of New Jersey at Cooper - Voorhees
 Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees
Ph: 856-325-6757
New Mexico
  Albuquerque
 Hematology Oncology Associates, PC
 Edward Libby
Ph: 505-938-5858
 University of New Mexico Cancer Center
 Clinical Trials Office - University of New Mexico Cancer Center
Ph: 505-272-6972
  Las Cruces
 University of New Mexico Cancer Center - South
 Edward Libby
Ph: 505-521-1554
  Santa Fe
 New Mexico Cancer Care Associates
 Clinical Trials Office - New Mexico Cancer Care Associates
Ph: 505-955-7910
New York
  Buffalo
 Roswell Park Cancer Institute
 Clinical Trials Office - Roswell Park Cancer Institute
Ph: 877-275-7724
  Glens Falls
 Charles R. Wood Cancer Center at Glens Falls Hospital
 Clinical Trials Office - Charles R. Wood Cancer Center at Glens Falls Hospital
Ph: 518-926-6700
  New York
 Mount Sinai Medical Center
 Luis Isola, MD
Ph: 212-241-6021
 New York Weill Cornell Cancer Center at Cornell University
 Clinical Trials Office - New York Weill Cornell Cancer Center at Cornell University
Ph: 212-746-1848
  Syracuse
 SUNY Upstate Medical University Hospital
 Clinical Trials Office - SUNY Upstate Medical University Hospital
Ph: 315-464-5476
North Carolina
  Goldsboro
 Wayne Memorial Hospital, Incorporated
 James Atkins, MD
Ph: 919-580-0000
  Kinston
 Kinston Medical Specialists
 Peter Watson, MD
Ph: 252-559-2200 ext. 201
North Dakota
  Fargo
 Veterans Affairs Medical Center - Fargo
 Glenn Shamdas
Ph: 701-239-3747
Ohio
  Akron
 McDowell Cancer Center at Akron General Medical Center
 Esther Rehmus, MD
Ph: 330-344-4673
  Canton
 Aultman Cancer Center at Aultman Hospital
 Clinical Trials Office - Aultman Cancer Center at Aultman Hospital
Ph: 330-363-6891
  Cleveland
 Case Comprehensive Cancer Center
 Clinical Trials Office - Case Comprehensive Cancer Center
Ph: 800-641-2422
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Bruce Averbook, MD, FACS
Ph: 216-778-4795
  Columbus
 Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
 Clinical Trials Office - OSU Comprehensive Cancer Center
Ph: 614-293-4976
 Email: osu@emergingmed.com
  Lima
 St. Rita's Medical Center
 Clinical Trials Office - St. Rita's Medical Center
Ph: 419-226-9617
Pennsylvania
  Danville
 Geisinger Cancer Institute at Geisinger Health
 Clinical Trials Office - Geisinger Cancer Institute
Ph: 570-271-5251
  Pittsburgh
 Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
 John Lister
Ph: 412-578-5000
  Scranton
 Hematology and Oncology Associates of Northeastern Pennsylvania
 Martin Hyzinski, MD
Ph: 570-558-3020
 Mercy Hospital Cancer Center - Scranton
 Martin Hyzinski, MD
Ph: 570-558-3020
  State College
 Geisinger Medical Group - Scenery Park
 Adel Makary, MD
Ph: 570-271-6045
  Wilkes-Barre
 Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
 Clinical Trials Office - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
Ph: 570-271-5251
Rhode Island
  Pawtucket
 Memorial Hospital of Rhode Island
 Humera Khurshid
Ph: 401-729-2000
South Carolina
  Charleston
 Hollings Cancer Center at Medical University of South Carolina
 Clinical Trials Office - Hollings Cancer Center at Medical University of South Carolina
Ph: 843-792-9321
South Dakota
  Sioux Falls
 Avera Cancer Institute
 Loren Tschetter, MD
Ph: 605-328-8000
 Medical X-Ray Center, PC
 Loren Tschetter, MD
Ph: 605-328-8000
 Sanford Cancer Center at Sanford USD Medical Center
 Clinical Trials Office - Sanford Cancer Center
Ph: 605-328-1367
Vermont
  Berlin
 Mountainview Medical
 Barbara Grant, MD
Ph: 802-847-8400
  Burlington
 Fletcher Allen Health Care - University Health Center Campus
 Clinical Trials Office - Fletcher Allen Health Care
Ph: 802-656-8990
Virginia
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center
Ph: 804-628-1939
Washington
  Bellingham
 St. Joseph Cancer Center
 Saul Rivkin, MD
Ph: 206-386-2929
  Bremerton
 Olympic Hematology and Oncology
 Saul Rivkin, MD
Ph: 206-386-2929
  Federal Way
 St. Francis Hospital
 Lauren Colman, MD
Ph: 253-403-1677
  Kennewick
 Columbia Basin Hematology
 Saul Rivkin, MD
Ph: 206-386-2929
  Puyallup
 Good Samaritan Cancer Center
 Lauren Colman, MD
Ph: 253-403-1677
  Seattle
 Group Health Central Hospital
 Clinical Trials Office - Group Health Central Hospital
Ph: 206-287-2900
 Minor and James Medical, PLLC
 Saul Rivkin, MD
Ph: 206-386-2929
 Polyclinic First Hill
 Saul Rivkin, MD
Ph: 206-386-2929
 Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
 Saul Rivkin, MD
Ph: 206-386-2929
 University Cancer Center at University of Washington Medical Center
 Clinical Trials Office - University Cancer Center at University of Washington Medical Center
Ph: 206-616-8289
  Spokane
 Cancer Care Northwest - Spokane South
 Clinical Trials Office - Cancer Care Northwest - Spokane South
Ph: 509-228-1083
  Tacoma
 Allenmore Hospital
 Lauren Colman, MD
Ph: 253-403-1677
 CCOP - Northwest
 Lauren Colman, MD
Ph: 253-403-1677
 Franciscan Cancer Center at St. Joseph Medical Center
 Clinical Trials Office - Franciscan Cancer Center
Ph: 253-426-6914
 Madigan Army Medical Center - Tacoma
 Jasmine Daniels
Ph: 206-968-1110
 MultiCare Regional Cancer Center at Tacoma General Hospital
 Clinical Trials Office - MultiCare Regional Cancer Center
Ph: 253-403-3229
 St. Clare Hospital
 Lauren Colman, MD
Ph: 253-403-1677
West Virginia
  Huntington
 Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
 Oncology Research Supervisor
Ph: 304-399-6617
Wisconsin
  Green Bay
 Green Bay Oncology, Limited at St. Mary's Hospital
 Thomas Saphner, MD, FACP
Ph: 920-884-3135
 Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
 Thomas Saphner, MD, FACP
Ph: 920-432-6049
 St. Mary's Hospital Medical Center - Green Bay
 Thomas Saphner, MD, FACP
Ph: 920-498-4200
 St. Vincent Hospital Regional Cancer Center
 Clinical Trials Office - St. Vincent Hospital Regional Cancer Center
Ph: 920-433-8889
  La Crosse
 Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
 Clinical Trials Office - Gundersen Lutheran Cancer Center
Ph: 608-775-2385
 Email: cancerctr@gundluth.org
  Marinette
 Bay Area Cancer Care Center at Bay Area Medical Center
 Thomas Saphner, MD, FACP
Ph: 715-735-6523
888-788-2070
  Oconto Falls
 Green Bay Oncology, Limited - Oconto Falls
 Thomas Saphner, MD, FACP
Ph: 920-846-3444
800-432-6049
  Sturgeon Bay
 Green Bay Oncology, Limited - Sturgeon Bay
 Thomas Saphner, MD, FACP
Ph: 800-432-6049
Wyoming
  Sheridan
 Welch Cancer Center at Sheridan Memorial Hospital
 Benjamin Marchello, MD
Ph: 307-674-6022

Related Information

Web site for additional information 1

Registry Information
Official Title Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
Trial Start Date 2005-05-02
Trial Completion Date 2010-03-29 (estimated)
Registered in ClinicalTrials.gov NCT00118209 2
Date Submitted to PDQ 2005-05-06
Information Last Verified 2008-10-20
NCI Grant/Contract Number CA31946

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.



Table of Links

1http://bethesdatrials.cancer.gov/lymphoma/nci05c0252
2http://clinicaltrials.gov/ct/show/NCT00118209